Top 5 Papers
#1
Source: Nature Medicine | Authors: Lee DJ, Baca S, Ng K (Dana-Farber Cancer Institute / Harvard Medical School) | Published: April 30, 2026
Score: 11/20 — Nature Medicine (9) + early-onset CRC focus / population-level epidemiology (+1) + biomarker / precision-prevention angle (+1)
Kimmie Ng's group at Dana-Farber published an exposome-wide analysis in Nature Medicine on April 30 systematically dissecting modifiable and environmental risk factors associated with early-onset colorectal cancer (EOCRC, age <50). The work integrates large-scale exposure datasets with cancer registries to identify drivers beyond inherited genetics — implicating dietary patterns, ultra-processed foods, microbiome perturbation, antibiotic exposure, sedentary behavior, and metabolic factors in the rising EOCRC incidence. EOCRC has nearly doubled in incidence among Americans <50 over the past two decades, and this paper provides the most granular exposome map yet for prevention and risk stratification. Practice implication: supports calls for earlier screening in higher-risk profiles and dietary/lifestyle counseling at primary-care level. Coming from arguably the leading EOCRC clinical research group, this is a landmark for the field.
Post angle: 🚨 Nature Medicine: Dana-Farber's Kimmie Ng group maps the EOCRC exposome.
• Early-onset CRC up ~2x in <50s over 2 decades
• Diet, microbiome, antibiotics, sedentariness all implicated
• Sets the stage for risk-stratified earlier screening
Prevention is the next frontier for EOCRC. #CRC #EOCRC #Prevention #PrecisionOncology
#2
Source: Lancet Oncology | Authors: Widder J, Bol GM, ... Guckenberger M (EORTC-ESTRO OligoCare consortium) | Published: May 2026
Score: 10/20 — Lancet Oncology (8) + Delphi consensus / systematic review (+2)
An EORTC-ESTRO OligoCare consortium consensus (30 experts + 5 patient representatives, 4 Delphi rounds) reviewed 121 trials of metastases-directed therapy (MDT) and proposed standardized endpoints for oligometastatic disease — relevant across colorectal, pancreatic, gastric, esophageal, and HCC oligomets. Overall survival reached the highest consensus as primary endpoint, but the panel formally endorsed two novel endpoints: polymetastatic progression-free survival (polyPFS) and start-or-switch of systemic therapy-free survival (SST-FS) — both designed to allow repeat MDT without classifying it as treatment failure. Time-to-deterioration of quality-of-life was added as a patient-prioritized secondary endpoint. Practice impact: this should reshape how SBRT, ablation, and metastasectomy trials in oligometastatic GI cancers are designed and reported, and aligns radiation oncology, medical oncology, and surgical trialists on a common vocabulary.
Post angle: 📐 Lancet Oncology: EORTC-ESTRO OligoCare Delphi consensus drops new endpoints for oligomets MDT trials.
• OS still king
• NEW: polymetastatic PFS, systemic-therapy-free survival
• Repeat MDT no longer = treatment failure
• Time to QoL deterioration prioritized by patients
Game-changer for SBRT/ablation trials in oligo CRC, HCC, PDAC. #Oligomets #Radonc #GIOnc
#3
Source: Erasca press release / OncLive coverage of AACR 2026 data | Authors: Erasca, Inc. | Published: April 27–28, 2026
Score: 9/20 — Press release / AACR data (6) + Phase 1 dose escalation with strong efficacy (+2) + biomarker-guided / KRAS precision (+1)
Erasca's pan-RAS(ON) inhibitor ERAS-0015 — designed to inhibit signaling across both mutant and wild-type RAS isoforms — produced unconfirmed ORRs of 40% in second-line-or-later KRAS G12X-mutant metastatic PDAC and 62% in 2L+ KRAS G12X-mutant NSCLC at pharmacologically active 16–32 mg QD doses in the first-in-human dose-escalation study. Adverse events were predominantly low-grade and no dose-limiting toxicities were reported. ERAS-0015 joins daraxonrasib (RMC-6236) in the emerging pan-RAS(ON) class targeting active GTP-bound RAS — the same mechanism that produced 13.2-vs-6.7-mo OS gains in RASolute 302 in 2L PDAC. With ~90% of PDAC harboring KRAS mutations, two clinically active pan-RAS inhibitors in this space transforms the trajectory for what was, for decades, the least druggable target in the GI cancer playbook.
Post angle: 🎯 ERAS-0015 pan-RAS(ON) Phase 1 data drop:
• 2L KRAS G12X PDAC: 40% ORR
• 2L KRAS G12X NSCLC: 62% ORR
• Mostly low-grade AEs, no DLTs
Second clinically active pan-RAS(ON) after daraxonrasib. The KRAS-PDAC fortress is officially under siege. #PDAC #KRAS #PanRAS #AACR2026
#4
Source: Cancer Medicine | Authors: Wang Y, Xu J, ... Rao C (Ningbo No. 2 Hospital, China) | Published: May 2026
Score: 9/20 — Other journal (5) + prospective Phase II (+2) + impressive PFS in heavily pre-treated mCRC (+2)
A Chinese prospective Phase II two-arm trial enrolled 40 patients with mCRC after ≥2 prior lines and tested oral fruquintinib (4 mg QD d1–21) + TAS-102 (30 mg/m² BID d1–5, 15–19) every 4 weeks, with or without SBRT to a metastatic site. Among 36 evaluable patients (50% had ≥3 metastatic organs; 80% had >5 lesions), ORR was 19.4% and DCR was 88.9%. Median PFS was 8.58 months — striking, given that single-agent fruquintinib (FRESCO-2) and TAS-102 each show ~3-month PFS in this setting. Median OS was not yet reached. The most common grade 3/4 AE was decreased lymphocyte count (12.5%); neutropenia/leukopenia were universal but mostly low-grade. No treatment-related deaths. The combination (with or without SBRT) is a plausible salvage option for fit, multi-line-refractory mCRC patients and warrants randomized validation against either monotherapy.
Post angle: 📊 Phase II: Fruquintinib + TAS-102 ± SBRT in 3L+ mCRC (n=40):
• ORR 19.4%, DCR 88.9%
• mPFS 8.58 mo (vs ~3 mo for either alone)
• 80% had >5 mets, 50% had ≥3 organs
• Manageable toxicity, no treatment-related deaths
Promising salvage signal — needs randomized validation. #CRC #mCRC #Fruquintinib #TAS102
#5
Source: Cancer Medicine | Authors: You R, Xu Q, ... Yin G (Jiangsu Cancer Hospital, China) | Published: May 2026
Score: 8/20 — Other journal (5) + retrospective propensity-matched (+1) + OS + PFS benefit (+2)
Retrospective single-center, propensity-matched (45 pairs, n=90) study of hepatic artery infusion chemotherapy (FOLFOX via HAIC) combined with regorafenib + sintilimab versus regorafenib monotherapy in MSS/pMMR colorectal cancer liver metastases refractory to ≥2 prior systemic lines. The HAIC-R-S triplet doubled both PFS (6.5 vs 3.4 mo, p<0.001) and OS (14.1 vs 8.1 mo, p<0.001), with ORR 37.8% vs 2.2% (p<0.001) and DCR 71.1% vs 42.2% (p=0.006). Grade ≥3 AEs were higher with the combination (26.7% vs 13.3%), driven by hematologic toxicity. This is hypothesis-generating only — no randomized data yet — but the magnitude of benefit in a population (refractory MSS CRCLM) with virtually no effective options is striking, and consistent with prior HAIC + checkpoint inhibitor signals in liver-dominant disease. Prospective multicenter trials needed before MSS CRCLM patients should be routinely offered this approach outside trials.
Post angle: 🩸 Retrospective propensity-matched: HAIC FOLFOX + rego + sintilimab vs regorafenib alone in 3L+ MSS/pMMR CRC liver mets (n=90):
• mOS 14.1 vs 8.1 mo (p<0.001)
• mPFS 6.5 vs 3.4 mo (p<0.001)
• ORR 37.8% vs 2.2%
• Grade ≥3 AEs 26.7% vs 13.3%
MSS CRCLM remains the toughest niche — needs randomized validation. #CRC #LiverMets #HAIC #MSS
Additional Papers of Interest
-
Lancet Oncology — Modeling study projects rising global cancer mortality through 2050, with GI cancers (CRC, gastric, liver, pancreatic, esophageal) representing major drivers in low- and middle-income countries. Workforce companion paper estimates oncology personnel scaling needed to bend mortality curves.
-
ASCO Educational Book — Comprehensive review covering KRAS G12C, BRAF V600E, HER2, MSI-H/dMMR, FGFR, EGFR, and emerging targets in mCRC; integrates BREAKWATER, SUNLIGHT, KEYNOTE-177, and ctDNA-guided escalation/de-escalation strategies.
-
Oncolytics Biotech press release (Apr 27) — FDA Type C meeting alignment on pivotal study design for pelareorep (oncolytic reovirus) + atezolizumab in unresectable metastatic anal SCC; potential first-line registrational path in a rare GI cancer subtype with limited options.
-
In Vivo — Single-arm Phase I shows acceptable safety and pCR signal for adjuvant SOX following standard CRT in locally advanced low rectal cancer; supports SOX backbone for future TNT regimens in Asian populations.
-
PNAS — Mechanistic study identifies the AP-1 transcription factor Fra-2 as a key determinant of response to the KRAS-G12D inhibitor MRTX-1133; Fra-2 high tumors are more resistant, suggesting a candidate biomarker for KRAS-G12D inhibitor patient selection in PDAC.
-
Scientific Reports — Integration of intratumoral CD45+CD3+ and CD3+CD8+ T-cell densities into multivariate nomograms improves overall and disease-free survival prediction in GEJ adenocarcinoma; supports a low-cost IHC-based stratification tool ahead of the molecular era.
Back to all digests